Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

New Medications for Obesity and Diabetes Detailed at ADA Meeting

Numerous clinical trial results of new medications and products for managing obesity and type 2 diabetes were presented at last month’s 83rd Scientific Sessions of the American Diabetes Association. Full results were simultaneously published in the literature, including the following:

Lancet — Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA

New England Journal of Medicine — Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Lancet — Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial

Lancet — Oral Semaglutide 50 Mg Taken Once per Day in Adults With Overweight or Obesity (Oasis 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Lancet — Efficacy and Safety of Once-Daily Oral Semaglutide 25 Mg and 50 Mg Compared With 14 Mg in Adults With Type 2 Diabetes (Pioneer Plus): A Multicentre, Randomised, Phase 3b Trial

Source: Lancet, New England Journal of Medicine